Pancreatic Cancer Research

ResearcherNankai UniversityNo recent work listed

Shaoxia Du

Matched on OpenAlex author ID A5054858212. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 9

  1. Apolipoprotein E2 inhibits mitochondrial apoptosis in pancreatic cancer cells through ERK1/2/CREB/BCL-2 signaling. Co-author DOI 10.1016/j.hbpd.2022.09.010↗
  2. The COL11A1/Akt/CREB signaling axis enables mitochondrial-mediated apoptotic evasion to promote chemoresistance in pancreatic cancer cells through modulating B… Co-author DOI 10.7150/jca.47032↗
  3. LAMC2 modulates the acidity of microenvironments to promote invasion and migration of pancreatic cancer cells via regulating AKT-dependent NHE1 activity. Co-author DOI 10.1016/j.yexcr.2020.111984↗
  4. Apolipoprotein E2 modulates cell cycle function to promote proliferation in pancreatic cancer cells via regulation of the c-Myc-p21Waf1 signalling pathway. Co-author DOI 10.1139/bcb-2018-0230↗
  5. Apolipoprotein E2 Promotes the Migration and Invasion of Pancreatic Cancer Cells via Activation of the ERK1/2 Signaling Pathway. First author DOI 10.2147/cmar.s284115↗
  6. Artemin regulates CXCR4 expression to induce migration and invasion in pancreatic cancer cells through activation of NF-κB signaling. Co-author DOI 10.1016/j.yexcr.2018.02.008↗
  7. Tenascin-C Modulates Cell Cycle Progression to Enhance Tumour Cell Proliferation through AKT/FOXO1 Signalling in Pancreatic Cancer. Co-author DOI 10.7150/jca.25926↗
  8. Fractalkine/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT/NF-κB cascade in pancreatic cancer cells. Co-author DOI 10.1002/cbf.3278↗
  9. Tenascin-C induces migration and invasion through JNK/c-Jun signalling in pancreatic cancer. First author DOI 10.18632/oncotarget.20160↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hui Wang · 9 shared papers, 2017–2023 · strength 1.11
  2. Xiaohong Shen · 9 shared papers, 2017–2023 · strength 1.11
  3. Jun Cai · 8 shared papers, 2017–2021 · strength 0.90
  4. Juan Wang · 3 shared papers, 2017–2020 · strength 0.30
  5. Beibei Xin · 3 shared papers, 2017–2018 · strength 0.23
  6. Wei Wei · 2 shared papers, 2017–2020 · strength 0.20
  7. Wei Wei · 1 shared paper, 2020 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.